Several other equities analysts have also recently issued reports on KALA. ValuEngine cut Kala Pharmaceuticals from a buy rating to a hold rating in a report on Friday, December 21st. HC Wainwright reiterated a buy rating and issued a $15.00 price target on shares of Kala Pharmaceuticals in a report on Thursday, December 27th. Zacks Investment Research upgraded Kala Pharmaceuticals from a hold rating to a buy rating and set a $5.50 price target on the stock in a report on Wednesday, January 2nd. Wedbush set a $51.00 price target on Kala Pharmaceuticals and gave the company a buy rating in a report on Wednesday, January 16th. Finally, Jefferies Financial Group started coverage on Kala Pharmaceuticals in a report on Thursday, March 14th. They issued a buy rating and a $15.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Kala Pharmaceuticals currently has an average rating of Buy and a consensus target price of $20.58.
Kala Pharmaceuticals stock opened at $7.60 on Tuesday. The stock has a market capitalization of $257.51 million, a P/E ratio of -3.06 and a beta of 1.73. Kala Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $17.39. The company has a current ratio of 10.41, a quick ratio of 10.17 and a debt-to-equity ratio of 0.67.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.23). As a group, equities analysts predict that Kala Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. American International Group Inc. boosted its holdings in Kala Pharmaceuticals by 34.3% during the fourth quarter. American International Group Inc. now owns 10,369 shares of the company’s stock worth $51,000 after buying an additional 2,646 shares during the last quarter. Rhumbline Advisers bought a new position in Kala Pharmaceuticals during the fourth quarter worth about $75,000. Bradley Foster & Sargent Inc. CT bought a new position in Kala Pharmaceuticals during the fourth quarter worth about $115,000. United Services Automobile Association boosted its holdings in Kala Pharmaceuticals by 33.6% during the fourth quarter. United Services Automobile Association now owns 24,218 shares of the company’s stock worth $118,000 after buying an additional 6,088 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Kala Pharmaceuticals by 12.4% during the fourth quarter. Squarepoint Ops LLC now owns 27,871 shares of the company’s stock worth $136,000 after buying an additional 3,071 shares during the last quarter. Hedge funds and other institutional investors own 67.20% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More: What are the Benefits of Index Funds?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.